The JAK2^V617F tyrosine kinase mutation in myeloproliferative disorders : Status report and immediate implications for disease classification and diagnosisTEFFERI, Ayalew; GILLILAND, D. Gary.Mayo Clinic proceedings. 2005, Vol 80, Num 7, pp 947-958, issn 0025-6196, 12 p.Article

Activation de la voie Notch par OTT-MAL dans les leucémies aiguës mégacaryoblastiques = The OTC-MAL fusion oncogene: another Notch in megakaryoblastic leukemiaBERNARD, Olivier A; GILLILAND, D. Gary; MERCHER, Thomas et al.MS. Médecine sciences. 2009, Vol 25, Num 8-9, pp 676-678, issn 0767-0974, 3 p.Article

JAK-2 mutations and their relevance to myeloproliferative diseaseLEVINE, Ross L; GILLILAND, D. Gary.Current opinion in hematology. 2007, Vol 14, Num 1, pp 43-47, issn 1065-6251, 5 p.Article

FLT3-activating mutations in acute promyelocytic leukaemia: a rationale for risk-adapted therapy with FLT3 inhibitorsGILLILAND, D. Gary.Baillière's best practice & research. Clinical haematology. 2003, Vol 16, Num 3, pp 409-417, issn 1521-6926, 9 p.Article

The roles of FLT3 in hematopoiesis and leukemiaGILLILAND, D. Gary; GRIFFIN, James D.Blood. 2002, Vol 100, Num 5, pp 1532-1542, issn 0006-4971, 11 p.Article

Molecular genetics of human leukemias: New insights into therapyGILLILAND, D. Gary.Seminars in hematology. 2002, Vol 39, Num 4, pp 6-11, issn 0037-1963, 6 p., SUP3Article

Role of FLT3 in leukemiaGILLILAND, D. Gary; GRIFFIN, James D.Current opinion in hematology. 2002, Vol 9, Num 4, pp 274-281, issn 1065-6251Article

The FIP1L1-PDGFRα kinase in hypereosinophilic syndrome and chronic eosinophilic leukemiaCOOLS, Jan; STOVER, Elizabeth H; WLODARSKA, Iwona et al.Current opinion in hematology. 2004, Vol 11, Num 1, pp 51-57, issn 1065-6251, 7 p.Article

Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndromeSTONE, Richard M; GILLILAND, D. Gary; KLION, Amy D et al.Seminars in oncology. 2004, Vol 31, Num 2, pp 12-17, issn 0093-7754, 6 p., SUP6Article

The expression of ETV6/CBFA2 (TEL/AML1) is not sufficient for the transformation of hematopoietic cell lines in vitro or the induction of hematologic disease in vivoANDREASSON, Patrik; SCHWALLER, Juerg; ANASTASIADOU, Ema et al.Cancer genetics and cytogenetics. 2001, Vol 130, Num 2, pp 93-104, issn 0165-4608Article

Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurinBARRY, Elly V; DARK, Jennifer J; COOLS, Jan et al.Blood. 2007, Vol 110, Num 13, pp 4476-4479, issn 0006-4971, 4 p.Article

KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in miceLING ZHAO; MELENHORST, Jan J; LIU, P. Paul et al.Blood. 2012, Vol 119, Num 6, pp 1511-1521, issn 0006-4971, 11 p.Article

Idl is a common downstream target of oncogenic tyrosine kinases in leukemic cellsTAM, Winnie F; GU, Ting-Lei; JING CHEN et al.Blood. 2008, Vol 112, Num 5, pp 1981-1992, issn 0006-4971, 12 p.Article

Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9KRIVTSOV, Andrei V; TWOMEY, David; GOLUB, Todd R et al.Nature (London). 2006, Vol 442, Num 7104, pp 818-822, issn 0028-0836, 5 p.Article

X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesisLEVINE, Ross L; BELISLE, Claude; WADLEIGH, Martha et al.Blood. 2006, Vol 107, Num 10, pp 4139-4141, issn 0006-4971, 3 p.Article

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412GROWNEY, Joseph D; CLARK, Jennifer J; ADELSPERGER, Jennifer et al.Blood. 2005, Vol 106, Num 2, pp 721-724, issn 0006-4971, 4 p.Article

The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemiaCOOLS, Jan; QUENTMEIER, Hilmar; HUNTLY, Brian J. P et al.Blood. 2004, Vol 103, Num 7, pp 2802-2805, issn 0006-4971, 4 p.Article

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target ofimatinib in idiopathic hypereosinophilic syndromeCOOLS, Jan; DEANGELO, Daniel J; CROSS, Nicholas C. P et al.The New England journal of medicine. 2003, Vol 348, Num 13, pp 1201-1214, issn 0028-4793, 14 p.Article

mTOR Complex 1 Plays Critical Roles in Hematopoiesis and Pten-Loss-Evoked LeukemogenesisKALAITZIDIS, Demetrios; SYKES, Stephen M; ANASTASIOU, Dimitrios et al.Cell stem cell. 2012, Vol 11, Num 3, pp 429-439, issn 1934-5909, 11 p.Article

Common and Overlapping Oncogenic Pathways Contribute to the Evolution of Acute Myeloid LeukemiasKVINLAUG, Brynn T; CHAN, Wai-In; DE SILVA, Inusha et al.Cancer research (Chicago, Ill.). 2011, Vol 71, Num 12, pp 4117-4129, issn 0008-5472, 13 p.Article

Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in MyelofibrosisPARDANANI, Animesh; GOTLIB, Jason R; JAMIESON, Catriona et al.Journal of clinical oncology. 2011, Vol 29, Num 7, pp 789-796, issn 0732-183X, 8 p.Article

Structural and numerical variation of FLT3/ITD in pediatric AMLMESHINCHI, Soheil; STIREWALT, Derek L; ALONZO, Todd A et al.Blood. 2008, Vol 111, Num 10, pp 4930-4933, issn 0006-4971, 4 p.Article

Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarraysYAMAMOTO, Go; NANNYA, Yasuhito; KOEFFLER, H. Phillip et al.American journal of human genetics. 2007, Vol 81, Num 1, pp 114-126, issn 0002-9297, 13 p.Article

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis : Recommendations from an ad hoc international expert panelTEFFERI, Ayalew; THIELE, Juergen; REILLY, John T et al.Blood. 2007, Vol 110, Num 4, pp 1092-1097, issn 0006-4971, 6 p.Article

Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotypeGROWNEY, Joseph D; SHIGEMATSU, Hirokazu; SPECK, Nancy A et al.Blood. 2005, Vol 106, Num 2, pp 494-504, issn 0006-4971, 11 p.Article